



## **Liberty Health Sciences Signs Agreement As First State Partner To Bring The Award-Winning PAX Era To The Florida Market**

**Toronto, ON – September 10, 2018** — Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: [LHSIF](http://LHSIF)) [www.libertyhealthsciences.com](http://www.libertyhealthsciences.com) (“Liberty” or the “Company”), a provider of trusted, high quality cannabis experiences, announced today that it has become the first brand partner for the PAX Era, an easy-to-use, temperature controlled portable cannabis oil vaporizer, in the Florida market.

The PAX Era vapor platform and compatible pod technology will be available in all of Liberty’s Cannabis Education Centers (CEC) locations and through delivery starting October 1, 2018. Liberty will offer several varieties of strains, designed for a wide array of uses and giving a broad range of choice to consumers.

“The opportunity, as the first brand partner to sell the PAX Era system in Florida reinforces our leadership position in the industry with a strong commitment to new product offerings and innovation,” said George Scorsis, CEO of Liberty Health Services. “We continue to provide the very best customer service and most diverse collection of brands on the market today, that encompass our pharmaceutical grade cannabis. The PAX Era is the most universally accepted, technologically advanced vaporizer in the world. We are thrilled to be working with the strong management team at PAX Labs. They are the unparalleled trailblazers in this space.”

Years in development, the PAX Era temperature-controlled portable oil vaporizer features PAX’s distinctive anodized aluminum shell, full color LED interface, and gestural controls. The PAX Era device is only compatible with Era Pods, which feature heat control technology that provides superior flavor and consistent vapor quality. The Era pods are engineered to prevent leaking and clogging and feature PAX’s proprietary SimpleClick design, allowing consumers to change between pod varieties quickly and easily.

### **About Liberty Health Sciences Inc.**

Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale and beyond. Liberty’s measured approach to expansion opportunities maximizes returns to shareholders, while keeping consumers’ well-being at the forefront of what we do. For more information, please visit: [www.libertyhealthsciences.com](http://www.libertyhealthsciences.com).

**About PAX Labs, Inc.**

Founded in 2007, the company is a leader in the design and development of premium cannabis vaporization technologies and devices. Headquartered in San Francisco, PAX Labs has revolutionized the industry through innovation and product design. PAX Labs has sold over one million PAX devices in the flower vaporizer category and introduced PAX Era, a connected, app-driven pod system for concentrates, in September 2016. For more information, please visit [pax.com](http://pax.com).

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:** This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the production and sale of Pax Era products in Florida and the Company's future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

**Media Contact:**

Dwain Schenck

203-223-5230

[dwain@schenckstrategies.com](mailto:dwain@schenckstrategies.com)

Stephanie Kubacki

Vice-President, Marketing

415-830-7337

[skubacki@libertyhealthsciences.com](mailto:skubacki@libertyhealthsciences.com)

#